Introduction: Erectile dysfunction (ED) is a common condition affecting men. Apomorphine is one of the oral medications that has been used in the management of ED, though over recent years, its use in the management of ED has dwindled.
Areas Covered: The authors review the evidence available for the use of apomorphine in the management of ED. A Medline search was performed searching for the articles related to the use of apomorphine in the treatment of ED from 2000 to present. The article reviews the erectogenic properties of apomorphine and evaluates its efficacy, suitability and tolerability in management of patients with ED.
Expert Opinion: Apomorphine SL is more effective than placebos in treating ED and is generally well tolerated in the sublingual formulation, causing tolerable side effects. Newer nasal-spray formulations provide faster efficacy. Its efficacy in patients with multiple co-morbidities is more limited. However, it is not as effective as PDE5-I in the treatment of ED. Its most significant strength is its safety profile. It may have a niche in the treatment ED in patients who have failed treatment with, or are intolerant to other well-established pharmacological treatment for ED (e.g., PDE5-Is). Apomorphine is not a first-line treatment option for patients with ED, especially as it is no more widely available in the western world.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/17425255.2012.727797 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson's Disease-Patient Perspective.
Medicina (Kaunas)
December 2024
Department of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, Poland.
The rapid growth of the number of advanced Parkinson's disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa-carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study was to evaluate patients' satisfaction and the factors influencing preferences for CSAI and LCIG. The research focused on individuals diagnosed with advanced PD undergoing DAT at the Neurology Department of the University Hospital in Katowice.
View Article and Find Full Text PDFCharacterising a New Sheep Model of Parkinson's Disease Using Unilateral Intracerebral Injection of 6-Hydroxydopamine Into the Substantia Nigra.
Eur J Neurosci
January 2025
Department of Anatomy, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
New therapeutic agents developed for treating neurological disorders are often tested successfully on rodents. Testing in an appropriate large animal model where there is longer lifespan and comparable brain size to humans should improve translational success and is frequently expected by regulatory bodies. In this project, we aimed to establish a novel sheep model of Parkinson's disease as a large-brained experimental model for translational research.
View Article and Find Full Text PDFInsulin and TLR4 Inhibitor Improve Motor Impairments in a Rat Model of Parkinson's Disease.
Iran J Pharm Res
June 2024
Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Insulin resistance is an important pathological hallmark of Parkinson's disease (PD). Proinflammatory cytokines during neuroinflammation decrease insulin sensitivity by suppressing insulin signaling elements. Toll-like receptor 4 (TLR4), the main receptor involved in neuroinflammation, is also associated with the pathogenesis of PD.
View Article and Find Full Text PDFLong-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.
Neurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
How well is the female population represented in clinical trials with infusion therapies for Parkinson's disease? A systematic review and metanalysis.
Eur J Neurol
January 2025
Parkinson and Movement Disorders Unit, Study Center for Neurodegenerative diseases (CESNE), Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padua, Padua, Italy.
Background: Parkinson's disease (PD) is a neurodegenerative disorder affecting both sexes, but differences exist between male and female in clinical manifestations, functional impact of symptoms and hormonal influences. Therefore, representativeness of females in PD trials indirectly determines the external validity of the clinical research in this field.
Objective: To estimate the representativeness of female in infusion therapy trials for advanced PD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!